Robert W. Carlson, MD, and Lee N. Newcomer, MD, MHA, on 20 Years of Improving Cancer Care Together: A Payer’s Perspective
2015 NCCN Annual Conference
Robert W. Carlson, MD, Chief Executive Officer of the National Comprehensive Cancer Network, and Lee N. Newcomer, MD, MHA, of UnitedHealthCare, discuss the value of NCCN Guidelines in determining coverage decisions, the future of affordable care, bundled payments, and the clear value approach.
Andrew D. Zelenetz, MD, PhD
Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, talks about the revolution in lymphoma treatment, which started with rituximab and continues with obinutuzumab, ibrutinib, and others.
Mary Lou Smith, JD, MBA
Mary Lou Smith, JD, MBA, of the Research Advocacy Network, discusses, from the perspective of a patient advocate, the value of the NCCN guidelines and the impact they have made on cancer care.
Samuel M. Silver, MD, PhD, and Al B. Benson III, MD, FACP, FASCO
Samuel M. Silver, MD, PhD, of the University of Michigan Comprehensive Cancer Center, and Al B. Benson III, MD, FACP, FASCO, of Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discuss the evolution of NCCN Guidelines, which are available free online, and the components that make them effective: a multidisciplinary approach, the participation of patient advocates, consistency, and affordability of the evidence.
Andrew J. Armstrong, MD, ScM
Andrew J. Armstrong, MD, ScM, of Duke Cancer Institute, discusses the recent practice-changing landmark studies that showed significant increases in survival for men with castration-resistant prostate cancer and led to updates in the NCCN Guidelines for this disease.
Clifford Goodman, PhD, and Peter B. Bach, MD, MAPP
Clifford Goodman, PhD, of the The Lewin Group, and Peter B. Bach, MD, MAPP, of Memorial Sloan Kettering Cancer Center, discuss the affordability of cancer care, the “financial toxicities” of high drug prices, and what could and should be done about it.